Starling Oncology, Inc. (STLN)
NASDAQ: STLN · Real-Time Price · USD
6.17
-0.03 (-0.48%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Starling Oncology Earnings Call Transcripts
Fiscal Year 2026
-
Achieved first fully profitable year, doubled down on capital-light growth, and expanded delegated contracts across multiple states. Pharmacy now drives over 60% of revenue with rising margins, and robust pipeline supports a 2027 goal to double capitated revenue.
-
Q2 2026 saw record revenue, positive adjusted EBITDA, and a successful refinancing that improved liquidity. New capitation contracts in Nevada, Oregon, and California drove growth, while guidance for 2026 was raised on strong specialty pharmacy performance.